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IN VITRO EQUIVALENCE STUDY OF GENERIC METFORMIN HYDROCHLORIDE
TABLETS UNDER BIOWAIVER CONDITIONS
Abstract
Background: Generic drugs are smarter alternative to expensive brands, it is bio- equivalent formula of
any branded drug. FDA approved that generic drugs are the safest to consume, the medicines meet the
similar manufacturing standards followed while producing an innovator drug, however, the color, shape,
taste and packaging of generics is different from the innovator product. In short, a generic drug should be
bioequivalent to its brand counterpart. Metformin was initially marketed under the name of Glucophage®,
and now the market is loaded by generics of different origin, and price variability. Method: Our study was
conducted to determine whether metformin generics are bioequivalent to the innovator drug Glucophage®.
In-vitro bioequivalence testing under Biowaiver conditions can predict bioequivalence in a safe, fast, and
less expensive method. Thus, study was performed on Metformin tablets to assess whether generics are
bioequivalent to the innovator and hence be interchangeable. Results: The quality control results of the
thickness, hardness, friability, disintegration, weight uniformity, content uniformity, and assay showed that
most metformin tablets complied with the USP 34 NF29 2011 specifications. Dissolution testing under
biowaiver conditions showed different results. All tablets of the generics and innovator Glucophage®
were able to dissolve by more than 85% within 15 min. Two generics were bioequivalent to the innovator
Glucophage® having f2≥ 50 in the three dissolution media. The rest of generics showed variable results.
Conclusion: Generics of metformin varied in their bioequivalency to the innovator Gluocophage®. This
variation could be explained by different excipients, and manufacturing conditions. In-vivo bioequivalence
testing should be conducted to confirm that the innovator could be safely interchangeable with the brand
and this variation won’t affect the safety and efficacy of the drug.
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1. INTRODUCTION
Diabetes is a chronic complex metabolic disorder that usually develops when the
endogenous insulin is insufficient to control the plasma glucose blood level because of
insufficient insulin , this condition requires continuous treatment and patient self-monitoring to
prevent its complications. Insulin, a hormone naturally secreted by the pancreas in response to
high glucose concentration, controls the body metabolism via regulating the body’s ability to
utilize and store glucose and fat. Among the different types of diabetes, type 2 is the most common
form making more than 90% of the cases. It is more common in patients who are obese, having
family history of diabetes, or gestational diabetes. They usually suffers from insulin resistance,
high triglyceride, and low high density lipoprotein (Yehuda, H. Z., et al. 2015). Metformin is
the most common used oral anti-hyperglycemic drug used for treating type 2 diabetes. It is
considered as the first line drug of choice for the treatment of type 2 diabetes, particularly in
overweight or obese people and those with normal kidney function. Metformin can lower basal
and post-prandial glucose levels. It produces its effect by decreasing hepatic glucose production,
decreasing intestinal absorption, and improving insulin sensitivity by increasing glucose uptake
and utilization. Metformin unlike other anti-diabetic doesn’t cause hypoglycemia, and
hyperinsulinemia. In addition to its anti-diabetic profile, metformin nowadays is used to treat
polycystic ovary syndrome (PCOS) which is a syndrome of ovarian dysfunction and
hyperandrogenism. Metformin, an insulin sensitizer, improves not only hyperandrogenism but
also ovulation and increases pregnancy rates in patients with PCOS. Recently, studies showed that
it may be beneficial in reducing the incidence of cancer.Bristol-Myers Squibb Company was the
first to introduce Metformin hydrochloride tablets in the market under the name of Glucophage®.
It was approved in 1994 in the USA. And now the market is full of different generics of metformin
hydrochloride. The main side effect of metformin is gastrointestinal disturbances. Metformin is
contraindicated in patients having their creatinine clearance less than30 ml/min (Drugs.com.
2019). Metformin hydrochloride is found in different dosage forms either immediate release (500,
850, 1000), or extended release dosage forms (500 XR, 750 XR, 1000 XR)

Metformin

Innovator drugs, also known as brands, are the first discovered and introduced drugs to the
market, its patency up to 10 years. After patent expiration, it can be copied under different generic
names. Generic must be bioequivalent to the original innovator having the same rate and extent,
dose, route of administration, use, side-effect, safety, and strength. They must be therapeutically
and pharmaceutically equivalent. They can only differ in their excipients, color, shape, and cost
(Olubukola O., et al 2012).
To verify that the brand is bioequivalent to the generic, in vivo and in vitro bioequivalence
tests must be done to assess compatibility of the products. The main limitation of the In-vivo tests
that make them unpractical is that generally their cost, time consuming, and invasiveness. In order
to reduce its use, the biopharmaceutics classification system must be used.
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Biopharmaceutical classification system (BCS), is a system that is used to classify drugs
according to their dose, solubility ratio, and intestinal permeability. For any drug to determine its
bioequivalency BCS should be done (Rohilla S., et al 2012).

Table 1: Biopharmaceutics classification system (BCS)
Class

Description

I

High solubility, High permeability

II

Low solubility, High permeability

III

High solubility, low permeability

IV

Low solubility, low permeability

Drugs classified as BCS class I , II, or III can be tested for their bioequivalence of brand
and generics using biowaiver dissolution testing according to the FDA, and WHO (Drugs.com.
2019, Rohilla S.,et al , 2012) Table 1. According to the WHO, and FDA (Rohilla S., et al 2012),
Biowaiver dissolution testing is a clinical bioequivalence testing for drugs having BCS I , II, or
III. The drugs tested must dissolve rapidly (≥85% dissolved within 15 min) in 3 different pH media
ranging from 1.2 to 6.8 having f2≥50 in the 3 medias. Biowaiver helps in predicting
bioequivalence in a safer, inexpensive, faster, and effective way than in–vivo testing. In addition,
it could be used for drugs of narrow therapeutic index. Certain criteria must be present to validate
this method. Where f2 is the similarity factor and f1 is the difference factor and calculated
according to the following formulas:
F1= {[Σnt=1|Rt-Tt|]/[Σt=1nRt]}×100
F2 = 50×log {[1 + (1/n)Σn=1(Rt – Tt)2]-0.5 x 100}
Where n is the number of dissolution sample times, Rt and Tt are the mean percent dissolved at
each time point, t, for the reference and test dissolution profiles, respectively. Criteria for
biowaiver:
To meet the biowaiver criteria, the tested drug must be highly soluble (highest dose is
soluble in 250 ml at pH 1.2-6.8), highly permeable (extent of absorption is greater than 85%), and
rapidly dissolving (85% or greater dissolves within 15 min). The dissolution must be performed
in 3 different pH media 1.2, 4.5, and 6.8 mimicking the gastric and intestinal fluids of the body
without enzymes. Twelve or six samples should be placed in 900ml buffer solution using either
the paddle type at 50 rpm or basket type at 100 rpm. 5ml samples to be withdrawn at different time
interval 10, 15,20,30,45, and 60min. The profiles of the test and reference products must be similar
in all 3 media having similarity factor f2≥50 (Rohilla S.,et al ., 2012).
Our studied drug metformin hydrochloride is BCS class III, and hence it is highly soluble
with low permeability and candidate for a biowaiver in vitro dissolution testing based on the WHO
classification system for class III drugs (Drugs.com. 2019, Rohilla S., et al, 2012).
This study sought to apply the BCS biowaiver requirements in order to assess the
equivalence of generic metformin tablets obtained from Lebanese, Egyptian, European, and
United Arab Emirate markets with the innovator GLUCOPHAGE® that is a registered trademark
of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Our study also
aimed to compare and evaluate the tested brand and generics by applying quality control tests
following the USP pharmacopeia.
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2. MATERIALS AND METHODS
2.1. Materials:
The drug samples investigated in our study were all immediate release solid dosage
forms, purchased from registered pharmacies in Lebanon and Egypt, and all were within
product expiration dates. The selection of these brands was done according to their
availability in the Egyptian and Lebanese markets.
Table 2: Coding Of Metformin Hydrochloride Tablets
Manufactured country

CODE
®

Batch number

Expiry Date

Germany

Innovator- Glucophage 1000 mg

ELE3901

NOV 2017

European

GM001 1000 mg

41071

FEB 2017

Egyptian

GM002 1000 mg

1573011

MAR 2017

Egyptian

GM003 1000 mg

01140533

AUG 2017

Emirate (U.A.E)

GM004 1000 mg

0040

OCT 2019

Lebanese

GM005 850 mg

LT9184

JAN 2017

All reagents used to prepare the buffer solutions were of analytical grade and provided
by Fluka. These were potassium chloride, sodium chloride, concentrated hydrochloric acid,
potassium dihydrogen phosphate, and Dihydrogen phosphate. Distilled water was used
throughout the work. Metformin hydrochloride authentic powder was a gift from CID co.
pharmaceuticals, Cairo, Egypt.

2.2. Method
2.2.1. Buffer solutions
The buffer solutions were prepared according to the EUROPEAN
PHARMACOPOEIA 5.0, and the pH was confirmed using a pH meter. Buffer solution
of pH 1.2 was prepared by dissolving 6.57 g of potassium chloride in distilled
water. 50ml of the solution was added to 85 ml of 0.2 M hydrochloric acid solution.
The solution was then diluted with distilled water till 200 ml volumetric flask. The
phosphate buffer solution of pH 4.5 was prepared by dissolving 6.8 g of potassium
dihydrogen phosphate in 1000 ml distilled water. The phosphate buffer solution of pH
6.8, was prepared from 2 solutions A (50ml), and B (22.4 ml) and completed to 200 ml
by distilled water. Solution A was prepared by dissolving 9.08 g of potassium
dihydrogen phosphate in 1L of distilled water, while solution B consisted of 0.2 M
sodium hydroxide (NaOH) (2g/L).

2.2.2. Standard metformin hydrochloride stock solution
In order to prepare the standard metformin hydrochloride stock solution,
100mg metformin hydrochloride reference standard was accurately weighted and
transferred into 100 ml volumetric flask, then completed to the line marked using
distilled water.
The wavelength was measured using Jasco® UV-vis spectrophotometer (Model
No.V-530). Absorption was measured at a range of 200-300 nm. The maximum
wavelength of standard Metformin Hydrochloride was found at 232 nm.
The Calibration curve was obtained by measuring the absorbance’s against blank
of different serial dilutions of metformin hydrochloride ranging from 0.4mg/ml to
1.4mg/ml. The calibration curve is shown in figure 1.
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Absorbance

Calibration curve

y = 0.7757x + 0.0302
R² = 0.9998

1.2
1
0.8
0.6
0.4
0.2
0

0.5
1
concentration (mg/ml)

1.5

Fig.1: Calibration Curve

2.2.3. Dissolution Rate Determination under Biowaiver conditions
The dissolution test carried in 3 pH media 1.2, 4.5, 6.8 was performed using the
Dissolution rate apparatus ERWEKA DT6R (Heusenstamm, GERMANY). 900 ml
buffer solution was placed in each compartment of the apparatus with one tablet placed
in each basket. The dissolution was performed at 100 rpm at a temperature of 37±0.5
Cº. Six units from each brand were evaluated in the three pH media. Sample aliquots
of 5 ml were withdrawn from a zone midway between the surfaces of the
dissolution medium to the top of the basket at specified time intervals
(5,10,15,30,45,60 min) and replaced with 5 ml of the appropriate medium to maintain
sink conditions. Samples were filtered using 0.45µm milipore filter paper, and diluted
100 folds with distilled water. The diluted samples were then analyzed
spectrophotometrically at 232 nm to determine the dissolved amount of metformin
hydrochloride. The dissolution system met the USP, BP, and the FDA performance
verification test requirements for dissolution testing under biowaiver conditions. The
percentage of drug dissolved was calculated using the following formula:
% Drug dissolved = [amount of drug dissolved (mg) / drug content per tablet (mg)]
×100.
The difference factor f1 and the similarity factor f2 was calculated for each generic
with respect to the innovator using the following formulas.
F1= {[Σnt=1|Rt-Tt|]/[Σt=1nRt]}×100
F2 = 50×log {[1 + (1/n)Σn=1(Rt – Tt)2]-0.5 x 100}
Where n is the number of dissolution sample times, Rt and Tt are the mean percent
dissolved at each time point, t, for the reference and test dissolution profiles,
respectively.

2.2.4 Quality control tests
 Tablet Thickness (mm): The thickness of metformin innovator and generic drugs was
measured using a micrometer. Ten tablets from each brand were examined. The
Average thickness was calculated and expressed in mm. The limit required by the
pharmacopeia should be ± 5% from the average weight calculated.
 Tablet hardness Test: The hardness of metformin innovator and generics was
measured using ERWEKA Monsanto hardness tester. Ten tablets from each smaple
were taken, and then each tablet was placed between the spindle of the machine until
the tablet breaks. The pressure required to break the tablets was recorded, and the
average hardness of the ten tablets was calculated and expressed in kg/cm2.
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 Friability Test: To determine the weight loss of the tablets after abrasion, ten intact
tablets from each sample were weighted and placed in the Roche Friabilator at 25
revolutions per minute (rpm) for 4 minutes. Dust was removed from the tablets before
re- weighting them. The Friability of the tablets were then calculated using the
following formula:
% friability = [initial wt –final wt]/initial weight ×100
 Uniformity of weight (mg): Twenty intact tablets from each tested sample were
weighed individually using a digital balance, then their average weight was calculated.
The uniformity of weight was calculated by the percentage deviation between the
weight of each tablet to the average weight of the 20 tablets.
 Disintegration: To determine the disintegration time required by each tablet, 6
tablets from each tested sample was placed in the ERWEKA (Heusenstamm,
Germany) disintegration apparatus at 37.2± 0.5 Cº in distilled water. The time taken
by each tablet to disintegrate completely was recorded. Complete disintegration is
defined when there was no more tablet residues left in the mesh.
 Assay: The assay was done to ensure that the actual amount of the active ingredient
present in the tablet is the same as the labeled amount. Twenty tablets from each sample
were weighted and powdered. From the powder, an amount equivalent to 0.1g of
Metformin hydrochloride was transferred to a 100ml volumetric flask. The powder
was dissolved in 70ml distilled water and shacked for 15 min, then diluted to 100ml
distilled water and filtered using filter paper. 10ml of the filtrate was then diluted to
100ml. This procedure was repeated one more time. The absorbance of the resulting
solution was measured at a wavelength of 232nm against blank. The amount in mg of
metformin hydrochloride present per portion was calculated using the following
formula:
10C (AU/AS)
Where C is the concentration of Metformin Hydrochloride reference standard in µg/ml,
and AU and AS are the absorbance’s obtained from assay preparation and standard
preparation respectively.
 Content uniformity: Ten tablets from each batch of the studied generics and innovator
were used to perform this test. Each tablet was firstly placed in 100ml volumetric flask.
50ml distilled water was added into the flask. Then the flask was shaken to ensure
complete dissolution of metformin, and completed till the line mark by distilled water.
0.1 ml was withdrawn from the prepared solution using a pipette and diluted in 100ml
distilled water. The absorbance of the following solution was measured at 232nm
against blank. The content uniformity was calculated by using the same formula of that
for the assay.

3. RESULTS
3.1 Dissolution Rate Determination
Figures 2, 3, and 4 illustrate the dissolution profile of the innovator and the five tested
metformin hydrochloride generics. The dissolution curves for each product reflects the
average dissolution time of six tablets. Table 3 showed the percentage dissolved of metformin
hydrochloride at each time interval. The results of pH 2 showed that, the dissolution of
Glucophage® and its generic ranged from 85.55% to 101.17% within 30 min. At pH 4.5,
Glucophage® recorded 87.77%, while its generics recorded higher readings from 90% till
96.67%. At pH 6.8, similar results were shown Glucophage® dissolved by 97.82% at 30 min,
and other generics dissolved between 97.82% and 105.43%. This result complied with the
USP metformin monograph, and the WHO specifications for dissolution rate determination
under biowaiver conditions. Dissolution profile of metformin generics was compared to the
innovator Glucophage® using the similarity factor f2, and the difference factor f1. For
GM001 and GM003, their similarity factor f2 had a value greater than 50 in the 3 dissolution
media and a low difference factor f1<15 indicating their bioequivalence to the innovator.
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Generics GM002, GM004, and GM005 failed to show their bioequivalence to
Glucophage® as they had a similarity factor less than 50 and a higher difference factor f1
ranging from 11 to 24 in the 3 dissolution media.

% Dissolution pH2
120
D
i 100
s
80
s
o 60
% l
u 40
t
20
i
o
0
n
0

Glucophage®
GM001
GM002

GM003
GM004
GM005
20

40

60

80

Time ( min )

Fig.2: Dissolution rate profile of Glucophage® innovator and generics in pH 2
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Fig.3: Dissolution rate profile of Glucophage® innovator and generics in pH 4.5
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Fig.4: Dissolution rate profile of Glucophage® innovator and generics in pH 6.8
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®
Table 3: Results of f2, and f1 calculations for Glucophage innovator and generics in different pH media
Glucophage
Time
(min)

®

GM001

GM002

GM003

GM004

GM005

%

%

%

%

%

%
Dissolved

Dissolved

Dissolved

Dissolved

Dissolved

Dissolved

5

35.29

31.76

50.59

35.29

43.52

71.76

10

44.70

40

60

42.35

68.23

75.29

15

55.29

75.29

92.94

57.64

96.47

76.47

30

89.41

90.59

101.17

85.88

97.64

96.47

45

98.82

96.47

101.17

94.11

100

96.47

60

100

101.17

101.17

101.17

100

96.47

f1=8

f1=20

f1=3

f1=19

f1=24

f2=53

f2=37

f2=76

f2=35

f2=33

pH 2

pH 4.5
5

35.55

36.67

55.55

36.67

50

48.89

10

47.77

54.44

83.33

51.11

63.33

64.44

15

62.22

73.33

85.55

56.67

67.78

72.22

30

87.77

95.55

90

92.22

96.67

96.67

45

101.11

100

102.22

101.11

100

100

60

101.11

100

102.22

101.11

100

100

f1=7

f1=19

f1=3

f1=11

f1=12

f2=60

f2=36

f2=73

f2=51

f2=49

pH 6.8
5

38.04

40.22

63.043

46.74

63.04

57.60

10

52.17

64.130

73.91

57.61

85.87

73.91

15

70.65

77.17

83.69

67.39

98.91

82.60

30

97.82

102.17

100

105.43

100

97.82

45

100

102.17

101.087

105.43

100

100

60

103.26

102.17

101.087

105.43

100

100

f1=6

f1=14

f1=7

f1=20

f1=12

f2=61

f2=42

f2=61

f2=34

f2=44
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3.2 Quality Control Tests:
Thickness, hardness, friability, uniformity of weight, disintegration, content uniformity,
and drug content per tablet (assay) were assessed and are shown in Table 4.
Table 4: Physiochemical Properties of Metformin Hydrochloride Tablets
Uniformity
of
weight(g)

Disintegration
time
(min)

0.043

1.071
± 0.015

15 :55
± 0:23

97.8
±0.55

101.00
± 1.26

23.56
±1.97

0.019

1.101*
±0.024

10:41
±0:38

98.0
±1.03

103.00
± 0.99

5.813
± 0.025

19.14
±1.622

0.022

1.165
±0.019

7:48
±0:10

GM003

6.412
± 0.058

12.21
± 2.25

0.007

1.068*
± 0.015

13:26
±1:58

GM004

6.706
±0.065

26.93
±3.49

0.021

1.14
±0.019

8:57
±0:05

GM005

6.85
± 0.042

15.58
±1.67

0.027

0.91*
±0.0093

7:24
±0:20

Thickness
(mm)

Hardness
2
(kg/cm )

Glucophage
®

6.457
±0.035

24.04
± 1.63

GM001

6.33
±0.035

GM002

Friability
%

Content
uniformity
(w/v%)

Assay
(w/v%)

105.39
±1.88

105.5
±1.55

98.50
± 1.5

95.2
±0.96
102.0
±0.61

104.50
± 1.55

94.4
±1.25

99.75
±1.47

-Uniformity of weight USP limit ± 5% weight of tablet
-Friability % limit < 1% Disintegration time within 15 min
USP range for Content Uniformity, and Assay 95%-105%
* One way analysis of variance ANOVA followed by post-hoc test indicating that the results were statistically significant
(p<0.01) than the innovator glucophag

4. Discussion:
Glucophage® and five available generics of Metformin Hydrochloride were examined for
their in-vitro equivalency under biowaiver conditions (Drugs.com. 2019, Rohilla S., et al, 2012).
The study also evaluated quality control tests (thickness, hardness, friability, disintegration,
uniformity of weight, content uniformity, assay, dissolution) according to the USP pharmacopeia
(USP 34 NF 29, 2011).
Dissolution:
Dissolution rate determination is considered among the most important in-vitro tests to
assess the quality of oral pharmaceutical solid dosage forms as tablets (Anand, O., et al, 2011).
Solubility, hydrophobicity of the formulation, amount of disintegrant, binder, and the
manufacturing method (compression force of the tablets) are considered among the main factors
influencing the dissolution rate of a drug. According to the USP 34 NF29 2011(USP 34 NF 29,
2011) metformin monograph, the accepted criteria for the dissolution of metformin tablets should
not be less than 75% of the labeled amount dissolved within 30 min.
Dissolution of metformin is an important aspect for drug bioavailability since it belongs to
a class III drug (Crison, J., et al, 2012) it must be solubilized in the aqueous environment of the
gastrointestinal tract to be absorbed. The dissolution profile of Glucophage® and its generics did
not show a wide variety in the results in the chosen pH media. In order to judge the bioequivalence
of the tested samples under biowaiver conditions, all dissolution profiles were compared to
that of the brand Glucophage® using the similarity factor f2 and the difference factor f1.
Published by Digital Commons @ BAU, 2020
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The higher the similarity factor f2, and the lower the difference factor f1, the more similar
the dissolution profile of the generic to the innovator will be. According to the WHO, a generic
is said to be bioequivalent to the innovator if the similarity factor f2 > 50 in 3 dissolution media
(Rohilla S., et al, 2012). GM001 and GM003 were bioequivalent to Glucophage® as they showed
f2 > 50 in 3 dissolution media. Regarding GM002, GM004, and GM005 their similarity factor
was not significant to show their equivalency to the innovator. This difference could be attributed
to various binders and disintegrates used by different companies. Based on this assessment, only
generic GM001, and GM003 can be interchanged with the innovator. Physical inspection of
Metformin tablets showed that almost all samples complied with the USP specifications.
Thickness:
Thickness of tablets depends on the shape of the tablet which differs from one company to
another. According to the USP the allowable percentage difference between each tablet and the
average thickness of 10 tablets is ± 10%. The average thickness of Glucophage® innovator was
6.457±0.035mm, and those of the generics ranged from 6.33±0.035 mm to 6.85±0.042 mm. All
the tablets of the generic and the innovator was within the specified range, thus the results
complied with the USP requirements. Tablet thickness may play a role in the patient compliance
(U.S. Department of Health and Human Services, CDER, (2015).
Hardness:
Hardness reflects the ability of tablets to withstand shipping, abrasion, transportation,
handling, and other breakage storage conditions. It is an important criterion as it affects both
disintegration, and dissolution. Tablets must be hard enough to withstand packaging and shipping,
and yet soft enough to disintegrate properly after swallowing. Compression pressure applied
during manufacturing, types of excipients as binder, and whether the tablets coated or not can
reflect the extent of tablet hardness (U.S. Department of Health and Human Services, CDER,
(2015). The hardness of Glucophage®, and its generic were tested and found to be very hard
compared to the USP34 NF29 2011(USP 34 NF 29, 2011) limit (5-8 kg). The average hardness of
the six batches ranged from 15.58 kg/cm2 - 24.04 kg/cm2 with Glucophage® recording the highest
results among its tested generics. All the tested tablets failed to pass the hardness test. This result
could be explained by the fact that the tablets are film coated to decrease their main side effect
which is gastrointestinal side effect. Also, different excipients presented in each generic may
explain the variety of hardness among the batches. The hardness of Metformin tablets didn’t affect
their solubility.
Friability:
Friability test is usually related to the hardness test. It is usually designed to assess the ability
of the tablets to resist corrosion. During manufacturing and handling process, tablets are subjected
to stressful conditions which can result in the removal of small fragments from the tablet surfaces
(U.S. Department of Health and Human Services, CDER, (2015). According to the USP 34 NF29
2011(USP 34 NF 29, 2011), the maximum weight loss accepted should not exceeds 1%.
Glucophage® friability was measured and found to have high percentage of friability compared
to other generics recording 0.043%. The rest of generics had lower friability % ranging from
0.007% to 0.027%. Our tested samples passed this test with % friability <1%.
In general dose variation between tablets is measured by two tests, the weight uniformity
and content uniformity test (USP 34 NF 29, 2011). Variation in weight may be attributed to either
poor flow properties of the powder or mechanical problems of the tablet machine (USP 34 NF 29,
2011).
Content uniformity:
Content uniformity is done to ensure a constant dose of drug between individual tablets.
The USP 34 NF29 2011(USP 34 NF 29, 2011) metformin monograph stated that the average
content of metformin hydrochloride tablets ranged from 95% to 105. The content uniformity of
the innovator, GM001, GM003, and GM004 were within the USP limit (95-105%) while GM002,
and GM005 were out of the specified limit.
Uniformity of weight:
According to the USP 2010 (USP 33 NF 28. 2010), the allowed percentage deviation for
tablets weighing more than 250 mg is ± 5% and not more than 2 tablets deviated outside the range,
and none deviates by more than twice the allowed percentage.
https://digitalcommons.bau.edu.lb/hwbjournal/vol2/iss2/1
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The weight of Metformin hydrochloride tablets ranged from 1.068 g for GM003 to 1.165 g
for generic GM002 except for generic GM005 0.91 g being lower in dose than the rest of the
generics. GM002 deviated out of the specified range, while the rest of the generics had an accepted
range and complied with the USP specifications except for GM002.
Disintegration:
Disintegration test aimed to test the ability of tablets to disintegrate within a prescribed time
when present in a liquid media (USP 34 NF 29, 2011). The average disintegration time of the
innovator Glucophage® was about 15:55 ± 0:23 sec and those of the generics ranging from 7:24
±0:20 sec to 13:26 ±1:58 sec. The results shown complied with the USP specification (USP 34 NF
29, 2011), and the BCS class of metformin which stated that the disintegration time for class III
BCS must not exceeds 15 min (Drugs.com. 2019, Rohilla S., et al , 2012).
Assay:
The assay method was used to prove that the amount of active ingredient of the product
batch is close to its label claim. The results obtained from the assessment of the % content of active
ingredients of the innovator and five tested generics of metformin hydrochloride showed values
within the monograph specifications (95%-105%).
Main limitations of the study:
According to the FDA and WHO, In-vitro bioequivalence under biowaiver conditions
could reflects the in-vivo bioequivalence for drugs classified as BCS 1,2,3 (Drugs.com. 2019,
Rohilla S., et al ,2012). Even though, the real bioavailability and bioequivalence of the drugs can
be confirmed and concluded by in-vivo studies. Factors such as human gastrointestinal tract with
its own nature, excipients used, and different manufacturing conditions could affect the dissolution
profile of the tested products. The study was conducted on only five generics of metformin
hydrochloride.

5. CONCLUSION:
The debate whether generics could be interchangeable with brand remains a controversial
issue. For that reason bioequivalence testing must be done to make a decision of which generic
could be substituted by the innovator. The quality of the marketed products of metformin, brand
and generics, was evaluated through quality control parameters done on the tablets.
They include tablet thickness, hardness, friability, disintegration, weight uniformity, content
uniformity, and assay. According to the USP 34 NF 29 2011 (USP 34 NF 29, 2011), any change
in these characteristics can significantly affect the safety and efficacy of the product. Glucophage®
and generics showed compliance with the USP specifications and limits.
In-vitro bioequivalence testing was conducted under the WHO biowaiver testing procedure
to determine whether generics could be interchangeable with the innovator Glucophage®.
Dissolution profiles revealed differences between GM002, GM004, and GM005 with respect to
the innovator Glucophage®. While GM001, and GM003 showed their bio-equivalency to the
innovator Glucophage®.
Now and along with our study’s result, we do recommend that Glucophage® could be
substituted firstly by GM001, and GM003. Even though, we cannot judge that the reset of generics
were not bio-equivalent to the innovator. In order to confirm the in-vitro results, in-vivo studies
should be implemented. The difference among generics could be referred to different excipients
used, various manufacturing conditions, and metformin’s low permeability may affects its
dissolution profile.
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